“In the third quarter, we reported very encouraging interim data showing that RLY-2608 + fulvestrant led to clinically meaningful progression free survival in heavily pre-treated patients with PI3Ka-mutated, HR+, HER2- metastatic breast cancer,” said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics (RLAY). “Based on these data, we are preparing to initiate a pivotal trial in 2L breast cancer in 2025, which we expect to be able to fully fund through top-line readout with our existing cash on hand. We also continue to progress our pre-clinical programs and look forward to bringing new programs into the clinic in 2025.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics participates in a conference call with JPMorgan
- Relay Therapeutics added to Analyst Current Favorites list at Raymond James
- Relay well-positioned to generate significant value with RLY-2608, says Stifel
- Relay Therapeutics price target raised to $19 from $18 at H.C. Wainwright
- Relay Therapeutics 28.6M share Secondary priced at $7.00
Questions or Comments about the article? Write to editor@tipranks.com